Gilead sees Descovy as successor to Truvada for HIV PrEP

With Truvada’s patent expiration imminent, Gilead is looking to Descovy to extend its hold on the HIV prevention market.

Gilead Sciences Inc. (NASDAQ:GILD) said Friday it submitted an sNDA to FDA for Descovy emtricitabine/tenofovir alafenamide for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. The company's Truvada emtricitabine/tenofovir is the only FDA-approved PrEP therapy; however, its U.S. patent expires in 2021...